Subscribe
shutterstock_2183087279_t_schneider
T. Schneider / Shutterstock.com
6 February 2024Big PharmaLiz Hockley

Eagle Pharma launches new suit over leukaemia drug

Oncology specialist seeks to block another bendamustine generic following trio of lawsuits in January | Firm filed complaint for patent infringement against Dr Reddy’s.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Eagle Pharmaceuticals asserts new patents with trio of lawsuits over cancer drug
23 January 2024   Complaints say Slayback, Apotex and Baxter Healthcare infringed two patents through NDAs for leukaemia drug injection | Eagle patents issued in last two months expire in 2031.
Americas
Teva and Eagle try to block Bendeka generic
1 July 2021   Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Teva and Eagle try to block Bendeka generic
1 July 2021   Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.
Big Pharma
Eagle Pharmaceuticals asserts new patents with trio of lawsuits over cancer drug
23 January 2024   Complaints say Slayback, Apotex and Baxter Healthcare infringed two patents through NDAs for leukaemia drug injection | Eagle patents issued in last two months expire in 2031.

More on this story

Americas
Teva and Eagle try to block Bendeka generic
1 July 2021   Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.
Big Pharma
Eagle Pharmaceuticals asserts new patents with trio of lawsuits over cancer drug
23 January 2024   Complaints say Slayback, Apotex and Baxter Healthcare infringed two patents through NDAs for leukaemia drug injection | Eagle patents issued in last two months expire in 2031.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers